Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.16    
    

 
 

RETIREMENT AGREEMENT    
    

November 21,
2006 

Dear
Dr. Gupta: 

        This
letter sets forth the agreement between you and GT Solar Incorporated, a Delaware corporation (the "Company," and together with GT
Solar International, Inc., a Delaware corporation, GT Solar Holdings, LLC, a Delaware limited liability company, and each of the Company's subsidiaries, the
"Group," and each individually a "Group Company"). By signing and delivering to the Company as provided
below this letter agreement (this "Agreement"), you and the Company hereby agree as follows: 

        1.    Retirement from the Company.    

        The
termination of your employment and the termination of your board membership with each Group Company (as applicable) will be effective on December 31, 2006 (the
"Retirement Date"). As of the Retirement Date, you will automatically (i) no longer be an employee or a director of any Group Company and
(ii) cease to be required to fulfill any of the duties and responsibilities associated with any of the aforementioned positions with any Group Company. In addition, the Employment Agreement by
and between you and the Company, dated as of December 30, 2005 (the "Employment Agreement") will terminate and be of no further force or effect
as of the Retirement Date. 

        2.    Severance Benefits.    

        In
exchange for your execution and delivery to the Company of this Agreement and the General Release in the form attached as  Exhibit A hereto (the "Release"), and only for so long as you comply with the Confidentiality and
Non-Competition Agreement (as defined below) and only for so long as you do not revoke, or attempt to revoke, the Release or otherwise assert in writing that the Release is unenforceable,
the Company agrees to provide you for a twenty-four (24) month period from and after the Retirement Date with all of the "Severance Benefits" (as defined in the Employment
Agreement) to which you would have been entitled pursuant to Section 3.7.1 of the Employment Agreement had you been terminated by the Company without "Cause" (as defined in the Employment
Agreement). Such Severance Benefits shall not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter established by the Company or
any Group Company, but shall be subject to all required and customary withholding by the Company or any Group Company. You understand that the Severance Benefits to you represent consideration for
signing the Release and are not salary, wages or benefits to which you were already entitled. You also acknowledge and represent that you have already received everything to which you were entitled by
virtue of your employment relationship and/or director relationship with the Company or any other Group Company. 

        3.    Confidentiality and Non-Competition Agreement.    

        (a)   Notwithstanding
the termination of your employment and directorships with the Group as set forth in this Agreement, you shall continue to be bound by the restrictions
set forth in that certain Confidentiality and Non-Competition Agreement by and between you and the Company, dated as of December 30, 2005 (the
"Confidentiality and Non-Competition Agreement"), on the terms set forth therein. The Company understands that you may have an interest in
certain projects related to the solar power industry, including, specifically, projects related to reflectometers, non-aqueous wafer cleaning systems, and single crystal technologies. Upon
your request on a case-by-case basis, the Company will consider waiving specific aspects of the Confidentiality and Non-Competition Agreement and, potentially,
licensing certain technologies to you on terms the Company considers commercially reasonable. However, any waiver or license by the Company would be in the Company's sole discretion and would be
subject to mutually agreeable terms. 

 

        (b)   As
you are aware, the Company is party to a license agreement (the "NREL Agreement") with the National Renewable Energy
Laboratory ("NREL") under which it has licensed certain technology from
NREL. Notwithstanding subsection (a) above, at your request the Company will, on reasonable commercial terms to be negotiated in good faith, (i) sublicense to you, for your use in
connection with projects related to reflectometers, certain of the technology it has licensed from NREL (provided that such sublicense is permitted under the terms of the NREL Agreement) and
(ii) waive provisions of the Confidentiality and Non-Competition Agreement to the extent necessary to permit you to pursue such projects based on such sublicense. 

        4.    Additional Agreements.    

        (a)   You
agree to reasonably cooperate with each Group Company in any internal investigation, administrative, regulatory, or judicial proceeding or dispute with a third
party. You understand and agree that your cooperation may include, but not be limited to, making yourself available to the Group or any Group Company upon reasonable notice for interviews and factual
investigations; appearing at the request of the Group or any Group Company to give testimony without requiring service of a subpoena or other legal process; volunteering to the Group pertinent
information; and turning over to the Group all relevant documents which are or may come into your possession all at times and on schedules that are reasonably consistent with your other permitted
activities and commitments. You understand that in the event the Company asks for your cooperation in accordance with this provision, the Company will reimburse you solely for reasonable travel
expenses (including lodging and meals) upon your submission of receipts. 

        (b)   You
agree not to disparage any Group Company, or any of such Group Company's past or present investors, officers, directors, members or affiliates or any of such members
or affiliates' officers, directors or employees. The Company agrees to cause each of its executive officers and directors not to disparage you. You further agree that as of the Retirement Date, you
will return to the Group any and all property, tangible or intangible, relating to its business, which you possessed or had control over at any time (including, but not limited to, company-provided
credit cards, building or office access cards, keys, computer equipment, manuals, files, documents, records, software, customer data base and other data) and that you shall not retain any copies,
compilations, extracts, excerpts, summaries or other notes of any such manuals, files, documents, records, software, customer data base or other data. 

        5.    Confidentiality of this Agreement.    

        The
contents of this Agreement (including the Release), including but not limited to its financial terms, are strictly confidential. By signing this agreement you agree and represent
that you will maintain the confidential nature of the Agreement (including the Release), except (a) to legal counsel, tax and financial planners, and immediate family who agree to keep it
confidential; (b) as otherwise required by law, in which case you shall notify the Company in writing in advance of disclosure; and (c) as necessary to enforce this Agreement. 

        The
Company agrees that it will keep the contents of this Agreement confidential, except (a) to its executive staff and governing bodies, as necessary or appropriate, and to its
outside counsel and auditors; (b) as otherwise required by law; and (c) as necessary to enforce this Agreement. 

        6.    No Transfer or Assignment.    

        You
and the Company agree that no interest or right you have or any of your beneficiaries has to receive payment or to receive benefits under this Agreement shall be subject in any
manner to sale, transfer, assignment, pledge, attachment, garnishment, or other alienation or encumbrance of any kind, except as required by law. Nor may such interest or right to receive payment or
distribution be taken, voluntarily or involuntarily, for the satisfaction of the obligations or debts of, or other claims against you or your beneficiary, including for alimony, except to the extent
required by law. 

2

 

        7.    No Admissions.    

        This
Agreement shall not be construed as an admission of any wrongdoing either by you or by the Company, its affiliates, or its and their directors, officers, agents and employees. 

        8.    No Other Agreement.    

        This
Agreement contains the entire agreement between you and the Company. No part of this Agreement may be changed except in writing, executed by both you and the Company. 

        9.    Third Party Beneficiaries.    

        The
Company's rights under this Agreement shall inure to the benefit of each other Group Company and to the officers, directors, employees, stockholders, members and affiliates of each
Group Company and its affiliates, and your rights to Severance Benefits under this Agreement shall inure to the benefit of you and your successors and permitted assigns. Except as set forth in the
preceding sentence, the parties hereto intend that this Agreement shall not benefit or create any right or cause of action in or on behalf of any person other than the parties hereto. The Company
shall require any successor to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent
that the Company would be
required to perform it if no such purchase had taken place, unless the Company at the time of such sale enters into other reasonable arrangements to protect your rights to receive Severance Benefits.
As used in this Agreement, "Company" shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement, by
operation of law or otherwise. 

        10.    Governing Law.    

        This
Agreement shall be interpreted in accordance with the laws of the State of New Hampshire. Whenever possible, each provision of this Agreement shall be interpreted in a manner as to
be effective and valid under applicable law, but if any provision shall be held to be prohibited or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating or affecting the remainder of such provision or any of the remaining provisions of this Agreement. 

        11.    Counterparts.    

        This
Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same Agreement. This Agreement
and any amendments hereto, to the extent signed and delivered by means of digital imaging and electronic mail or a facsimile machine, shall be treated in all manner and respects as an original
contract and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person. 

*
* * * * * 

3

        Please
indicate your agreement by signing this letter and returning it to us on or before 11/21, 2006. 

	 	 	Very truly yours,
	

 	
 	
GT SOLAR INCORPORATED
	

 	
 	
By:	

/s/  THOMAS M. ZARRELLA      
 Name: Thomas M. Zarrella

Title: President

AGREED
TO AND ACCEPTED BY: 

	

/s/  KEDAR P. GUPTA      
 Kedar P. Gupta	

 	

 

Dated:
11/21, 2006 

  

 
 

GENERAL RELEASE    
    

        I, Kedar P. Gupta, in consideration of and subject to the performance by GT Solar Incorporated, a Delaware corporation (together with GT Solar
International, Inc., a Delaware corporation, GT Solar Holdings, LLC, a Delaware limited liability company, and each of the Company's subsidiaries, the
"Company"), of its obligations under the Employment Agreement. dated as of December 30. 2005 (the "Employment
Agreement") and the Retirement Agreement, dated as of the date hereof (the "Retirement Agreement"), do hereby release and
forever discharge as of the date hereof the Company and its affiliates and all present and former directors, officers, agents, representatives, employees, successors and assigns of the Company and its
affiliates and the Company's stockholder and the affiliates, officers, manager, members and indirect owners thereof (collectively, the "Released
Parties") to the extent provided below. 

	1.
	I
understand that any payments or benefits paid or granted to me under Section 2 of the Retirement Agreement represent, in part, consideration for signing this General Release
and are not salary, wages or benefits to which I was already entitled. I understand and agree that I will not receive the payments and benefits specified in Section 2 of the Retirement
Agreement unless I execute this General Release and do not revoke this General Release within the time period permitted hereafter or breach this General Release. I also acknowledge and represent that
I have received all payments and benefits that I am entitled to receive (as of the date hereof) by virtue of any employment by the Company.

	2.
	Except
as provided in paragraph 4 below and except for the provisions of the Retirement Agreement which expressly survive the termination of my employment with the Company, I
knowingly and voluntarily (for myself, my heirs, executors, administrators and assigns) release and forever discharge the Company and the other Released Parties from any and all claims, suits,
controversies, actions, causes of action, cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and
attorneys' fees, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date this General Release becomes effective and enforceable) and whether known or
unknown, suspected, or claimed against the Company or any of the Released Parties which I, my spouse, or any of my heirs, executors, administrators or assigns, may have, which arise out of or are
connected with my employment (or board membership) with, or my separation or termination from, the Company or any Group Company (for the avoidance of doubt, excluding rights and claims in any other
capacity, including as the owner of any equity interest in GT Solar Holdings, LLC; including, but not limited to, any allegation, claim or violation, arising under: Title VII of the Civil Rights Act
of 1964, as amended; the Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit Protection Act); the Equal Pay Act of 1963, as
amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act of 1993; the Worker Adjustment Retraining and Notification Act; the Employee Retirement Income Security Act of
1974; any applicable Executive Order Programs; the Fair Labor Standards Act; or their state or local counterparts; or under any other federal, state or local civil or human rights law, or under any
other local, state, or federal law, regulation or ordinance; or under any public policy, contract or tort, or under common law; or arising under any policies, practices or procedures of the Company;
or any claim for wrongful discharge, breach of contract, infliction of emotional distress, defamation; or any claim for costs, fees, or other expenses, including attorneys' fees incurred in these
matters) (all of the foregoing collectively referred to herein as the "Claims").

	3.
	I
represent that I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by paragraph 2 above. 

6

 
	4.
	I
agree that this General Release does not waive or release any rights or claims that I may have under the Age Discrimination in Employment Act of 1967 which arise after the date I
execute this General Release. I acknowledge and agree that my retirement from employment (and from my board memberships) with the Company in compliance with the terms of the Retirement Agreement shall
not serve as the basis for any claim or action (including, without limitation, any claim under the Age Discrimination in Employment Act of 1967). This General Release also does not waive or release
any rights or claims that I may have against the Company (i) to any salary accrued or accruing on or after November 1, 2006 through the Retirement Date, or vacation pay accrued or
accruing through the Retirement Date, in each case to the extent unpaid as of the date hereof, and/or to reimbursement pursuant to the Company's existing reimbursement policies for
out-of-pocket expenses incurred in the ordinary course of business prior to the Retirement Date; (ii) under "COBRA" rights and similar state laws; if any,
(iii) under the Company's certificate of incorporation or bylaws, insurance policies, or otherwise, to be indemnified, contributed to, or held harmless from and against liabilities incurred by
reason of my service as a director, officer, or employee of the Company; and (iv) for the avoidance of doubt, under the Limited Liability Company Agreement of GT Solar Holdings, LLC, dated as
of December 30, 2005 (the "LLC Agreement") or the Registration Rights Agreement dated as of December 30, 2005, by and among the GT
Equipment Technologies, Inc., me, and certain others. To induce the Company to enter into the Retirement Agreement, I hereby represent and warrant to the Company that I am not aware of any
basis for any claim for any breach of the LLC Agreement or such Registration Agreement, or for breach of any other obligation of any Group Company, whether arising from rights relating to my
employment, my status as holder of equity or debt interests in any Group Company or any other of my capacities, as of or immediately prior to the execution of this General Release.

	5.
	In
signing this General Release, I acknowledge and intend that it shall be effective as a bar to each and every one of the Claims. I expressly consent that this General Release shall
be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding any state statute that
expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims hereinabove mentioned or implied. I
acknowledge and agree that this waiver is an essential and material term of this General Release and that without such waiver the Company would not have agreed to the terms of the Agreement. I further
agree that in the event I should bring a Claim seeking damages against the Company, or in the event I should seek to recover against the Company in any Claim brought by a governmental agency on my
behalf, this General Release shall serve as a complete defense to such Claims. I further agree that I am not aware of any pending Claim as of or immediately prior to the execution of this General
Release.

	6.
	I
agree that neither this General Release, nor the furnishing of the consideration for this General Release, shall be deemed or construed at any time to be an admission by the Company,
any Released Party or myself of any improper or unlawful conduct.

	7.
	I
agree that if I violate this General Release by suing the Company or any of the other Released Parties in respect of any Claim, I will pay all costs and expenses of defending against
the suit incurred by any of the Released Parties, including reasonable attorneys' fees, and return all payments received by me pursuant to the Retirement Agreement.

	8.
	Notwithstanding
anything in this General Release to the contrary, this General Release shall not relinquish, diminish, or in any way affect any rights or claims arising out of the
Retirement Agreement. 

7

 
	9.
	Whenever
possible, each provision of this General Release shall be interpreted in, such manner as to be effective and valid under applicable law, but if any provision of this General
Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other
provision or any other jurisdiction, but this General Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been
contained herein. 

BY
SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT: 

	(i)
	I
HAVE READ IT CAREFULLY;

	(ii)
	I
UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF
1967, AS AMENDED, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY ACT OF 1963, THE AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF
1974, AS AMENDED;

	(iii)
	I
VOLUNTARILY CONSENT TO EVERYTHING IN IT;

	(iv)
	I
HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO;

	(v)
	I
HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS RELEASE SUBSTANTIALLY IN ITS FINAL FORM TO CONSIDER IT;

	(vi)
	I
UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE
REVOCATION PERIOD HAS EXPIRED;

	(vii)
	I
HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT; AND

	(viii)
	I
AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED
REPRESENTATIVE OF THE COMPANY AND BY ME. 

	DATE: 11/21, 2006	 	/s/  KEDAR P. GUPTA      
 Kedar P. Gupta

8

QuickLinks

Exhibit 10.16

RETIREMENT AGREEMENT

GENERAL RELEASEQuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.15    
    

 
 

LICENSE AND SUPPLY AGREEMENT    
    

effective
as of the 23rd day of April, 2007 ("Effective Date")

is entered into between 

PERKINELMER LAS, INC.

Having a principal place of business at 940 Winter Street,

Waltham, MA 02451

(hereinafter "PE") 

and 

HELICOS BIOSCIENCES CORPORATION

Having a principal place of business at One Kendall Square, Building 700,

Cambridge, MA 02139

(hereinafter "HELICOS") 

(each
of which is referred to as a "Party", and collectively referred to as the

"Parties") 

PREAMBLE  

        PE is the owner of the entire right, title and interest in and to the Licensed Patents, as defined below, and Helicos desires a license under the Licensed Patents
in the Field. PE is willing to grant such a license under the following terms and conditions. 

1.     Definitions  

        In this Agreement, unless the context otherwise requires: 

	1.1
	"Affiliate"
shall mean any entity that directly or indirectly controls, or is controlled by a Party to this Agreement. The term "control" as used herein means (a) in the case
of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; or (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such
non-corporate entities.

	1.2
	"Commercial
Use" shall mean sales to third parties by Helicos of a Licensed Product or Licensed Service.

	1.3
	"Confidential
Information" shall mean confidential or other proprietary information that is disclosed by either Party to the other Party under this Agreement, including, without
limitation, hardware and software designs, product specifications and documentation, business and product plans and other confidential business information whether in a written or
non-written format. Confidential Information shall be marked as confidential at the time of disclosure or otherwise designated as confidential by the disclosing Party within thirty
(30) days of disclosure. Confidential Information shall not include information which: (i) is or becomes public knowledge without any action by, or involvement of, the receiving Party;
(ii) is disclosed by the receiving Party with the prior written approval of the disclosing Party; (iii) is independently developed by the receiving Party without use of the disclosing
Party's Confidential Information; (iv) is intentionally disclosed by the disclosing Party about the disclosing Party's own information to a third party without restriction on disclosure;
(v) is rightfully received by the receiving Party from a third party without a duty of confidentiality. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

1

 
	1.4
	"Diagnostics"
shall mean a Licensed Product and/or the sale, or offer for sale thereof, requiring the registration or approval of the U.S. Food and Drug Administration of the Licensed
Product before the same may be sold or offered for sale in the United States.

	1.5
	"End-User"
means an unrelated third party, other than a distributor or other intermediary, who is the ultimate user of Licensed Product or ultimate recipient of Licensed
Service.

	1.6
	"Exploit"
shall mean to import, make, have made, use, sell, offer for sale, sell through distributors, develop, commercialize, seek necessary or desirable regulatory approvals,
export, transport, distribute, promote and market.

	1.7
	"Field"
shall mean life science research and Commercial Use, but specifically excludes all Diagnostics applications.

	1.8
	"Helicos
Instrument" shall mean hardware manufactured by or on the behalf of Helicos and sold by Helicos.

	1.9
	"Helicos
Proprietary Reagent" shall mean any reagent developed by Helicos and subject to claims in a patent application filed by Helicos and that do not infringe a Licensed Patent.

	1.10
	"Lead
Time" shall mean the time period between the acceptance by PerkinElmer of a Purchase Order and the delivery date of the Nucleotide Analog Products ordered under such Purchase
Order.

	1.11
	"Licensed
Patent" shall mean any and all patents and patent applications listed in Appendix A attached hereto. Any continuations, divisionals,
continuation-in-part, re-examination, reissue, and all foreign counterparts of the patents and patent applications listed in Appendix A shall also be
included within the Licensed Patents.

	1.12
	"Licensed
Product" shall mean chemical reagents sold by Helicos that contain a component that would, but for the license granted herein, infringe one or more Valid and Enforceable
Claim(s) of the Licensed Patents. For the avoidance of doubt, Licensed Products shall include all reagents sold by Helicos that are not a Helicos Proprietary Reagent, whether sold separately or
bundled together, as long as at least one reagent would, but for the license granted herein, infringe one or more Valid and Enforceable Claim(s) of the Licensed Patents, but shall not include
associated hardware.

	1.13
	"Licensed
Service" shall mean a service provided by Helicos that includes the use of a Licensed Product.

	1.14
	"Net
Sales" shall mean sales recognized by Helicos or its Affiliates under generally accepted accounting principles attributable to the sale of a Licensed Product or Licensed Service
(whether directly or indirectly, including sales via sublicensees, distributors, dealers etc) less deductions for returns, rebates, volume discounts, sales taxes and other taxes directly linked to the
sales, and customary duties and transportation costs incurred by Helicos or its Affiliates.

	1.15
	"Nucleotide
Analog Product" shall mean one of the products listed in Appendix B attached hereto, including any revisions, enhancements, modifications and/or replacements
thereto. The Nucleotide Analog Product or its use may be covered by one or more of the Licensed Patents. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

2

 
	1.16
	"Purchase
Order" shall mean a written purchase order, indicating the quantity of each Nucleotide Analog Product and its delivery date,that is delivered to PE in accordance with
Section 4.3.

	1.17
	"Purchase
Price" shall mean the amount to be paid by Helicos to PE for the Nucleotide Analog Products as determined in accordance with Section 4.1.

	1.18
	"Term"
shall mean the period beginning on the Effective Date and terminating on the date this Agreement is terminated under Article 10.

	1.19
	"Territory"
shall mean the world.

	1.20
	"Valid
and Enforceable Claim" shall mean a claim of a Licensed Patent that has not been held to be invalid or unenforceable by a court or administrative body of competent
jurisdiction in a proceeding from which no appeal can be or has been taken within the relevant time for doing so. 

Plurals
can be read in the singular and vice versa. 

2.     License Grant  

	2.1
	Grant
of License for Licensed Product

	(a)
	PE
hereby grants to Helicos and Helicos hereby accepts a non-exclusive, non-assignable, non-transferable, non-sublicensable, royalty
bearing, worldwide license under the Licensed Patents to Exploit Licensed Product and Licensed Service for End-Users for use in the Field in the Territory.

	(b)
	It
is understood by the Parties that this license grant of Section 2.1 carries with it an implied license to End-Users of Helicos to use the Licensed Product or
Licensed Service in the Field but not to resell the Licensed Product or Licensed Service.

	(c)
	Helicos
shall provide direct End-User customer support.

	2.2
	Royalty.
This license grant of this Article 2 is subject to the payment of the royalty fees set forth in Article 3.

	2.3
	Product
Marking. The rights granted in this Article 2 above are conditioned on Helicos including in every manual (or the
equivalent thereof) for every Licensed Product or Licensed Service on and after the Effective Date, in every printed catalog describing the Licensed Product or Licensed Service within six
(6) months from and after the Effective Date, and in the electronic media version of Helicos' catalog within one (1) week from and after the Effective Date, the following notice: 

"Limited Use License for End Users
  For RESEARCH USE ONLY, NOT FOR DIAGNOSTIC PURPOSES. End user does not have a right to resell or transfer the nucleotide analog components of this kit either
alone or as
components of another product. No other rights are conferred and other uses are strictly prohibited."

	2.4
	Limitations.
The license grant set forth in Section 2.1 above does not include the right by Helicos to sell a stand-alone Nucleotide Analog Product other than (a) for
use on a Helicos Instrument or (ii) as a component of or replacement part of a Licensed Product. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

3

 

3.     Royalty Payments and Accounting  

	3.1
	Royalty.
Helicos shall pay to PE: i) [***] of Net Sales of Licensed Products and Licensed Services for the first [***] of Net
Sales of Licensed Products or Licensed Services by Helicos; ii) [***] Net Sales by Helicos of Licensed Products and Licensed Services between
[***], and iii) thereafter [***] of Net Sales by Helicos of Licensed Products and Licensed Services in excess of [***]
for the remaining term of this Agreement. For the avoidance of doubt, the payment calculations under this Paragraph shall be based upon a cumulative total of Net Sales and shall not be reset on an
annual or any other basis.

	3.2
	Payment.
Payments under this Article 3 shall be made by Helicos within thirty (30) calendar days of the last day of each calendar year quarter based upon Net Sales in
the preceding calendar year quarter, with each calendar year quarter ending on the last day of March, June, September, and December.

	3.3
	Records.
Helicos shall keep complete and accurate records of Net Sales in accordance with generally accepted accounting principles. Such records shall be available to PE and its
auditor, or a third party mutually agreeable to PE and Helicos, for inspection, at PE's expense, during normal business hours for three (3) years after the end of the relevant royalty period.
Notwithstanding the foregoing, if such inspection reveals that reported royalties have been understated by more than five percent (5%), then Helicos shall reimburse PE for reasonable expenses incurred
by PE, or its designee, for such inspection. 

4.     Purchase Price and Nucleotide Analog Product Delivery  

	4.1
	Purchase
Price. Throughout the Term, the Purchase Price for any Nucleotide Analog Product shall be based on yearly quotes negotiated between the Parties. The current Purchase Price is
set forth in Quote No.[***], which shall remain in effect until its expiration on [***]. After [***], and at its sole option, PE
can alter the Purchase Price in line with market based pricing adjustments.

	4.2
	Taxes.
Helicos's Purchase Price does not include any applicable sales, use, service, value added, or like taxes, however designated, levied against the sale, licensing, delivery or
use of the Nucleotide Analog Products. Helicos shall pay all such taxes imposed on the Nucleotide Analog Products, and, when PE has the legal obligation to collect such taxes, the appropriate amount
shall be added to Helicos's invoice and paid by Helicos. Helicos shall not be liable for any taxes based on Helicos's net income or for which it has provided to PE an appropriate exemption certificate
for the delivery jurisdiction, provided, however, that Helicos shall promptly notify PE of any amendment or revocation of such certificate.

	4.3
	Purchase
Order Procedure. All orders for Nucleotide Analog Products submitted by Helicos shall be initiated by a written Purchase Order sent to PE and requesting a delivery date
during the Term. No order shall be binding upon PE until a Purchase Order has been accepted by PE in writing, and PE shall have no liability to Helicos with respect to Purchase Orders that are not
accepted, except as otherwise provided herein. PE shall notify Helicos of the acceptance or rejection of a Purchase Order and of the accepted delivery date for accepted orders within five
(5) business days after receipt of the Purchase Order. If Helicos is not notified of PE's acceptance or rejection within five (5) business days of receipt of the Purchase Order by PE,
the Purchase Order shall be deemed accepted by PE. Helicos's Purchase Orders submitted to PE with respect to the Nucleotide Analog Products to be purchased hereunder shall be governed by the terms of
this Agreement. Nothing contained in any such Purchase Order shall in any way modify such terms of purchase or add any additional terms or conditions except as otherwise agreed in writing by the
Parties. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

4

 
	4.4
	Forecast.
Helicos shall, on a quarterly basis, provide PE with a six (6) month non-binding rolling projection of orders by Helicos of the Nucleotide Analog Products
("Forecast"). PE cannot guarantee that additional amounts of the Nucleotide Analog Products submitted on the Forecast will be available for purchase by Helicos. Helicos commits to purchasing at least
ninety percent (90%) of the amount of Nucleotide Analog Products submitted for the first three (3) months of the rolling forecast; however, notwithstanding any other provision contained herein,
the Parties acknowledge and agree that the Forecast can in no way be construed as a commitment on Helicos's part to purchase one hundred percent (100%) of the amount of Nucleotide Analog Products
submitted on the Forecast.

	4.5
	Lead
Time. To facilitate PE's production scheduling, Helicos shall submit Purchase Orders to PE consistent with a Lead Time of sixty (60) calendar days.

	4.6
	Payment.
Helicos shall make full payment of the Purchase Price for the Nucleotide Analog Products to PE in United States dollars, net thirty (30) calendar days from Helicos's
receipt of an undisputed invoice from PE. In the event that Helicos fails to make payments when due, PE shall notify Helicos in writing of the non-payments, and Helicos shall have twenty
(20) calendar days to cure the non-payment. In the event Helicos fails to cure such non-payment, such non-payment will be considered a material breach by
Helicos, and PE may alter terms of payment, suspend credit, withhold shipment, and/or terminate this Agreement.

	4.7
	Shipping.
All orders are F.O.B. factory. All Nucleotide Analog Products delivered pursuant to the terms of this Agreement shall be delivered by Helicos's standard carrier. Upon
delivery by PE to the carrier, the Nucleotide Analog Products shall be deemed delivered in accordance with the Purchase Order, and all title, ownership, and risk of loss or damage with respect to the
Nucleotide Analog Products shall pass to Helicos. All freight, insurance, taxes, and other shipping expenses shall be paid by Helicos. Items shipped after their scheduled delivery date will be shipped
by PE on an expedited overnight basis with the surcharge for such expedited overnight delivery being at PE's sole expense.

	4.8
	Inspection.
Helicos shall use reasonable efforts to inspect all Products and to furnish to PE, in writing, any claim that Helicos may have in connection with such Products within
30 days of receipt, for any Material Defect in the Nucleotide Analog Product. Within thirty (30) days of receipt of such written claim, and upon Helicos's return to PE, at PE's sole
expense, of the defective Nucleotide Analog Product, PE shall, at its sole option, repair or replace the Nucleotide Product or provide credit of the Purchase Price to Helicos. Such remedy shall be
Helicos's sole remedy for defective product. 

5.     Independent Contractors  

        The relationship of PE and Helicos established by this Agreement is that of independent contractors, and nothing contained in this Agreement shall be construed to
(i) give either Party the power to direct and control the day-to-day activities of the other, (ii) constitute the Parties as partners, joint venturers,
co-owners or otherwise as participants in a joint or common undertaking, or (iii) allow either Party to create or assume any obligation on behalf of the other Party for any purpose
unless expressly provided herein. Except as set forth in Article 10, nothing in this Agreement shall preclude either Party from developing, manufacturing, marketing, selling, leasing or
maintaining any products to or for any other customer, including, without limitation, end-users, original equipment manufacturers or other resellers. 

6.     Limited Warranty  

	6.1
	Nucleotide
Analog Products. PE warrants that the Nucleotide Analog Products shipped under this Agreement will be free from any defects in material and workmanship. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

5

 
	6.2
	Disclaimer.
PE MAKES NO WARRANTY OF ANY OTHER KIND, EITHER EXPRESS OR IMPLIED, AND SPECIFICALLY NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE LICENSED
PRODUCTS MAY BE USED WITHOUT INFRINGING THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTIES. NOTIFICATION OF ANY BREACH OF A PE WARRANTY MUST BE MADE TO PE IN WRITING WITHIN SIXTY
(60) DAYS OF RECEIPT OF LICENSED PRODUCT. NO CLAIM SHALL BE HONORED IF HELICOS FAILS TO NOTIFY PE WITHIN THE PERIOD SPECIFIED. THE SOLE AND EXCLUSIVE REMEDY OF HELICOS FOR ANY LIABILITY OF PE
OF ANY KIND INCLUDING LIABILITY BASED UPON WARRANTY (EXPRESS OR IMPLIED WHETHER CONTAINED HEREIN OR ELSEWHERE), STRICT LIABILITY, CONTRACT, OR OTHERWISE IS LIMITED TO THE REPLACEMENT OF THE LICENSED
PRODUCT OR THE REFUND OF THE INVOICE PRICE THEREOF. PE SHALL NOT IN ANY CASE BE LIABLE FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. 

7.     Confidentiality  

        During the Term and for a period of five (5) years following the expiration or earlier termination of this Agreement, the Parties agree to observe complete
confidentiality with respect to the Confidential Information, and to make all reasonable efforts not to disclose, or permit any third party or entity access to, the Confidential Information (or any
portion thereof) without the prior written permission of
the other Party (except such disclosure or access which is required to perform any obligations under this Agreement) and to ensure that any employees, or any third parties who obtain access to the
Confidential Information, are advised of the confidential and proprietary nature thereof and are prohibited by a written agreement from copying, utilizing or otherwise revealing the Confidential
Information. Without limiting the foregoing, the Parties agree to employ with regard to the Confidential Information procedures no less restrictive than the strictest procedures used by it to protect
its own confidential and proprietary information. Neither Party may use the Confidential Information for any purpose other than to fulfill its obligations under this Agreement. If either Party is
required to disclose pursuant to any judicial or governmental order, then the receiving Party must give the disclosing Party sufficient prior notice to contest such order. Notwithstanding the
foregoing, either party may disclose this Agreement with financial terms redacted to Government agencies or as otherwise required by law or regulation. 

8.     Indemnification and Insurance  

	8.1
	Indemnification.
PE and its Affiliates, and their directors, officers, employees and agents shall have no liability for damages incurred by Helicos resulting from actual or threatened
claims (including claims of inducement to infringe, demands, costs, damages, settlements, and liabilities (including all reasonable attorneys' fees and court costs)) of any kind whatsoever, regardless
of the form of such claims, relating to or arising out of the use, manufacture and/or sale by Helicos of Licensed Product or Licensed Services, and Helicos shall indemnify, defend, and hold harmless
PE and its Affiliates, and their directors, officers, employees and agents against all such claims except to the extent any such claim is shown by Helicos to have been caused directly and solely by
the gross negligence or willful misconduct of PE.

	8.2
	Insurance.
Helicos shall carry and maintain in force as long as its indemnification obligations remain in force, at Helicos's expense, insurance of the type and of the minimum
coverage limits as follows:

	(a)
	Damage,
including Contractual Liability, to cover Helicos' obligations under this Agreement, in a combined single limit—$2,000,000 per occurrence and a maximum of
$3,000,000 per annum. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

6

 

	(b)
	Other
insurance appropriate for Helicos' business or required by law. 

9.     Alleged Infringement of Licensed Patents  

        Helicos shall advise PE promptly upon its becoming aware of any third party's infringement of the Licensed Patents. PE shall at all times remain the owner of the
Licensed Patents with the sole right to enforce the Licensed Patents. 

10.   Termination  

	10.1
	Term.
This Agreement will become effective upon signature by both Parties and, unless terminated sooner as provided herein below or by mutual agreement, will remain in force and will
expire upon the expiration of the last to expire of the Licensed Patents on a country-by-country basis.

	10.2
	Termination
for Cause. Failure by either Party to this Agreement to comply with any of the obligations and conditions contained herein shall entitle the other Party to give the Party
in default written notice requiring it to cure such default. If the default is not remedied within sixty (60) days after receipt of such notice, the notifying Party shall be entitled, without
prejudice to any of its other rights conferred on it by this Agreement, to terminate the entire Agreement by giving notice to take effect immediately. The right of either Party to terminate the entire
Agreement as provided herein shall not be affected in any way by its waiver of or failure to take action with respect to any previous default.

	10.3
	Termination
for Insolvency. This Agreement shall terminate, upon notice by either Party, (i) if the other Party files voluntary bankruptcy proceedings, (ii) if
involuntary insolvency, receivership or bankruptcy proceedings instituted against the other Party are not dismissed within sixty (60) calendar days of such institution, (iii) upon the
other Party's making an assignment for the benefit of creditors, or (iv) upon the other Party's dissolution or ceasing to do business.

	10.4
	Termination
by either Party. Either Party may terminate this Agreement with a ninety (90) day prior written notice to the other Party.

	10.5
	Fulfillment
of Orders upon Termination. Upon termination of this Agreement for other than Helicos's material default or insolvency, PE shall continue to fulfill, subject to the terms
of Article 4, all Purchase Orders accepted by PE prior to the effective date of termination.

	10.6
	Survival.
The provisions of Articles 1, 5, 6, 8, 9, 10, 11, and 12 shall survive the expiration or earlier termination of this Agreement for any reason. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

7

   11.   Miscellaneous  

	11.1
	Amendment.
No amendments, changes, modifications or alterations of this Agreement shall be binding upon either party unless in writing and signed by both parties.

	11.2
	Headings.
All titles and captions in this Agreement are for convenience only and shall not be interpreted as having any substantive meaning.

	11.3
	Severability.
In the event that a court of competent jurisdiction holds that a particular provision or requirement of this Agreement is in violation of any law, such provision or
requirement shall not be enforced but replaced by a valid and enforceable provision or requirement which will achieve as far as possible the economic business intentions of the parties. All other
provisions and requirements of this Agreement, however, shall remain in full force and effect.

	11.4
	Entire
Agreement. This Agreement sets forth the entire agreement and understanding of the Parties relating to the subject matter herein and merges all prior discussions between them.
No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the Party to be charged.

	11.5
	Consents
and Approval. Except where expressly provided as being in the discretion of a Party, where approval, acceptance, consent or similar action by either Party is required under
this Agreement, such action shall not be unreasonably delayed or withheld. An approval or consent given by a Party under this Agreement shall not relieve the other Party from responsibility for
complying with the requirements of this Agreement, nor shall it be construed as a waiver of any rights under this Agreement, except as and to the extent otherwise expressly provided in such approval
or consent. Each Party shall, at the request of the other Party, perform those actions, including executing additional documents and instruments, reasonably necessary to give full effect to the terms
of this Agreement.

	11.6
	Mutually
Negotiated. The Parties agree that the terms and conditions of this Agreement (including any perceived ambiguity herein) shall not be construed in favor of or against any
Party by reason of the extent to which any Party or its professional advisors participated in the preparation of the original or any further drafts of this Agreement, as each Party has been
represented by counsel in its negotiation of this agreement and it represents their mutual efforts. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

8

 
	11.7
	Notices.
All notices and other communications hereunder shall be in writing and shall be deemed effective when delivered by hand or by facsimile transmission, when telexed or upon
receipt when mailed by registered or certified mail (return receipt requested), postage prepaid, to the Parties at the addresses and fax numbers specified as follows, or to any address and fax number
later provided by one party to the other: 

	PE	 	Helicos
	

PerkinElmer LAS, Inc.

Attn: President

940 Winter Street

Waltham, MA 02451

FAX: (781) 663-5972	
 	

Helicos BioSciences Corporation

One Kendall Square, Bldg. 700

Cambridge, MA 02139

Attn: Mark Solakian
	

With a copy to:	
 	

 
	

PerkinElmer LAS, Inc.

Attn: General Counsel

940 Winter Street

Waltham, MA 02451

FAX: (781) 663-5969	
 	

 

	11.8
	Force
Majeure. Except for the obligation to make payments, neither Party will be liable for any failure or delay in its performance under this Agreement due to any cause beyond its
reasonable control, including acts of war, acts of God, earthquake, flood, fire, embargo, riot, sabotage, labor shortage or dispute, governmental act, or failure of third party power or
telecommunications networks, provided that the delayed Party: (a) gives the other Party prompt notice of such cause, and (b) uses its reasonable commercial efforts to promptly correct
such failure or delay in performance. Notwithstanding the foregoing, if such event causes a delay in performance of more than sixty (60) days, the unaffected Party shall have the right to
terminate this Agreement without penalty upon written notice at any time prior to the affected Party's resumption of performance.

	11.9
	Assignment
and Binding Effect. Neither Party shall assign this Agreement to any third party without the prior written consent of the other Party; provided, however, that either party
may assign this Agreement to an Affiliate or a legal successor in interest to all or substantially all of the business or assets of such party without the prior written consent of the other party.
This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their permitted successors and assigns.

	11.10
	Legal
Expenses. The prevailing Party in any legal action brought by one Party against the other and arising out of this Agreement shall be entitled, in addition to any other rights
and remedies it may have, to reimbursement for its expenses, including court costs and reasonable attorneys' fees.

	11.11
	Counterparts.
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

	11.12
	Publicity.
Neither party shall issue a press release or disclose publicly the terms of this Agreement without the prior written approval of the other party except as required by
law, Government agencies or court orders. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

9

 
	11.13
	Construction.
The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and no rule of strict construction shall
be applied against either Party. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the
context requires otherwise. Any reference herein to "including" shall be interpreted as "including without limitation". Any reference to any Article, Section or paragraph shall be deemed to refer to
an Article, Section or paragraph of this Agreement, unless the context clearly indicates otherwise.

	11.14
	Conflict.
Notwithstanding any other provision contained herein, in the event of any conflict between the terms and conditions of this Agreement and any exhibits and/or appendices
attached hereto or referenced herein, the terms and conditions of this Agreement shall control and prevail.

	11.15
	Waiver.
No delay or omission by either Party to exercise any right or power it has under this Agreement shall impair or be construed as a waiver of such right or power. A waiver by
any Party of any breach of any covenant or provision of this Agreement shall not be construed to be a waiver of any succeeding breach of any other covenant or provision. All waivers must be in writing
and signed by the Party waiving its rights. 

12.   Governing Law and Jurisdiction  

        Any dispute under this Agreement shall be governed by the laws of the Commonwealth of Massachusetts without regard to its conflict of laws provisions and each
party agrees to submit to the jurisdiction of the appropriate court in Massachusetts. 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

10

 

        IN
WITNESS WHEREOF the Parties have entered into this Agreement as of the Effective Date. 

	 	 	PerkinElmer LAS, Inc.
	

 	
 	

By:	
 	

/s/ Kenneth S. King

	

 	
 	

Title:	
 	

Vice President and General Manager Molecular Medicine PerkinElmer Life and Analytical Sciences
	

 	
 	

Date:	
 	

 
	

 	
 	
Helicos BioSciences Corporation
	

 	
 	

By:	
 	

/s/ Thomas Meyers

	

 	
 	

Title:	
 	

Vice President and Chief Patent Counsel
	

 	
 	

Date:	
 	

April 23, 2007

       

       

       

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

11

 
Appendix A  

[***]

       

       

      

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

12

 
Appendix B  

[***] 

  

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT
UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

13

 
Appendix C  

Customer Services Quotation  

	Please reply to: PerkinElmer Life and Analytical Sciences

549 Albany Street, Boston, MA 02188

US: (617) 350-9400

International: (617) 350-9076

Fax: (617) 542-4330

Date: 01/29/07	 	In response to your inquiry, we are pleased to offer this quotation on the product(s) you require. Unless otherwise stated, process and delivery specified will remain open for a period of ninety (90) days from the date of
this quotation. Orders placed are subject to acceptance by PerkinElmer Life and Analytical Sciences, Inc., TERMS: NET 30 DAYS
	

To:	
 	

Dr. Philip R. Buzby

Helicos BioSciences Corp.

Building 200

One Kendall Square

Cambridge MA 02139	
 	

Ref#: 62219

PerkinElmer Quotation: 62219

Shipping Method: Air Express

Shipping Charges: Included

Shipping Point: dest

By: Patrice Fiore
	

 	
 	

Phone: 617-551-4750	
 	

Fax: 617-551-4751

 

	Description
 
	 	Quantity
	 	U/M
	 	Price

	Product Name: [***]	 	[***]	 	Lot	 	 

Specific Activity: N/A 

Catalog
number: [***] 

Delivery
ARO: 1 to 1 Week(s) 

Radiochemical
Purity >= N/A 

Other
Analysis: 

Optical
Purity: N/A 

Determined
By: 

Recommended
Shipping Solvent: N/A 

Recommended
Concentration: N/A 

Shipped
on (ice type): 

Comments:
[***] 

	NOTE: This quotation is subject to revision of synthetic details.	 	AGREED TO AND ACCEPTED:
	

IMPORTANT INFORMATION	
 	

BY:
	 	 	TITLE:
	 	 	DATE:
	This quotation includes all of the provisions on the face hereof and delivered herewith. Only such instructions, terms and conditions shall constitute the agreement between the parties hereto. The acceptance
copy must be signed and returned to: PerkinElmer Life and Analytical Sciences	 	 
	

This service is performed exclusively for purposes of scientific experimentation, analysis or chemical research. The products of this service are for laboratory use for research purposes.	
 	

 

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF
THE SECURITIES ACT; [***] DENOTES OMISSIONS. 

14

QuickLinks

Exhibit 10.15

LICENSE AND SUPPLY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]